Background: The purpose of this study was to investigate prognostic significance of fascin1 in nasopharyngeal carcinoma (NPC) and evaluate the association of fascin1 with tumor invasion.
introduction Nasopharyngeal carcinoma (NPC) is a distinctive type of head and neck cancer particularly common in Southeast Asia, with an incidence rate >20 per 100 000 people per year in this region [1] . NPC has a 5-year disease-specific survival rate of 53% and occurs more frequently in men than in women, at a ratio of approximately 3 : 1 [2, 3] . NPC patients tend to present at a more advanced stage of disease because the primary anatomical site of tumor growth is located in a silent area, and they exhibit higher metastatic potential when compared with other head and neck squamous cell carcinomas [4, 5] . Screening and early detection in populations at risk have been proposed to decrease both the morbidity and mortality associated with NPC. However, at present, we are unable to accurately make a prognosis on the basis of histological changes. Although a number of biological markers such as vascular endothelial growth factor (VEGF) [6] , Met protein expression level [7] , and the number of granzyme B-positive tumor-infiltrating lymphocytes [8] have been proposed to be valuable for the prognosis of NPC, no genotypic/phenotypic criteria currently exist for predicting which NPC will progress. Thus, it is urgent to find new biological markers that can help improve the diagnosis and prognosis of NPC.
Tumor metastasis is the major cause of death in cancer patients [9] . One of the hallmarks of invasive tumor cells is the increased cell motility. Fascin1, an actin-bundling protein, is one of the key molecules involved in cell motility. Fascin1 binds to the filamentous actin molecules and cross-links them to form hexagonal bundles. This can help form the cellular structures critical to cell movement, such as filopodia and spikes. Fascin1 is normally expressed in mesenchymal, neuronal, and endothelial cells but absent or at very low levels in epithelial cells [10, 11] . However, expression of fascin1 has been observed in several epithelial carcinomas, including the breast [12, 13] , ovary [14] , colon [15, 16] , esophagus [17] , stomach [18] , lung [19] , pancreas [20] , and bladder [21] . The aberrant expression of fascin1 in these cancers has been indicated to be linked to increased cell motility and tumor invasiveness. Hashimoto et al. [22] hypothesized that fascin1 up-regulation is generally correlated with the aggressive behavior of carcinoma cells, independent of the tissue of origin.
Given the importance of fascin1 in the development of epithelial carcinomas, we sought to investigate fascin1 expression in human NPC and assess its correlation with clinicopathological parameters, overall survival (OS), and disease-free survival (DFS) in NPC patients.
materials and methods

samples and patients
This retrospective study was conducted on a total of 161 paraffin-embedded NPC samples from NPC patients who were histologically and clinically diagnosed at Nanfang Hospital, Southern Medical University (Guangzhou, Guangdong, China) from 1998 to 2002. Thirty-three samples of benign nasopharyngeal diseases were used as controls. Four fresh NPC and paired noncancerous normal tissues were collected for western blot analysis. Tumor stage was defined by using the Chinese 1992 staging system as described before [2] . None of the patients had received chemotherapy or radiotherapy at the time the tissue samples were taken. Samples for diagnostic purposes were taken with the consent from each patient. The study was approved by the Institutional Review Board of the Nanfang Hospital, Southern Medical University. The characteristics of the 161 NPC patients are described in Table 1 . The median follow-up time for OS was 66 months for patients still alive at the time of analysis and ranged from 33 to 82 months.
cell lines
The NPC cell lines CNE1, CNE2, SUNE-1, 6-10B, and 5-8F were cultured in RPMI-1640 medium (GIBCO BRL, Rockville, MD) supplemented with 10% fetal bovine serum (FBS) and 100 U/ml penicillin/streptomycin. Cells were grown in 5% CO 2 humidified atmosphere at 37°C.
western blotting
Cells and tissues were washed twice with cold phosphate-buffered saline (PBS) and lysed on ice in radio immuno precipitation assay buffer (1 · PBS, 1% Nonidet P-40, 0.1% sodium dodecyl sulfate (SDS), 5 mM EDTA, 0.5% sodium deoxycholate, and 1 mM sodium orthovanadate) with protease inhibitors. The protein lysates separated electrophorectically on 10% SDS-polyacrylamide gel and transferred onto polyvinylidene fluoride membranes (Immobilon P, Millipore, Bedford, MA). Membranes were blocked with blocking buffer (5% nonfat dry milk in TBST (100 mM NaCl, 50 mM Tris, and 0.1% Tween-20)) for 1 h. Membranes were immunoblotted with anti-fascin1 mAb (Chemicon, Temecula, CA) and anti-b-actin antibody (Santa Cruz Biotechnology, Santa Cruz, CA) overnight at 4°C, followed by their respective secondary antibodies conjugated to horseradish peroxidase (HRP). The signals were detected by enhanced chemiluminescence (Pierce, Rockford, IL).
immunohistochemistry
Immunohistochemical staining was carried out using the Dako Envision System (Dako, Carpinteria, CA) following the manufacturer's recommended protocols. Briefly, all paraffin sections of 4-lm thickness were baked for 1 h at 65°C. Sections were deparaffined with xylenes and rehydrated. Sections were submerged into EDTA antigenic retrieval buffer (pH 8.0) and microwaved for antigenic retrieval. After being treated with 0.3% H 2 O 2 for 15 min to block endogenous peroxidase, the sections were treated with 1% bovine serum albumin for 30 min to reduce nonspecific binding and then incubated with mouse anti-fascin1 mAb (1 : 500; Chemicon) overnight at 4°C. After washing, the sections were incubated with HRP at 4°C for 30 min and then diaminobenzidine as enzyme substract. Fascin1 staining in endothelial cells of microvessels in each specimen was used as positive control. For negative controls, the primary antibody was replaced with normal goat serum.
evaluation of staining
The immunohistochemically stained tissue sections were scored separately by two pathologists blinded to the clinical parameters. For fascin1 assessment, the entire tissue section was scanned to assign the scores. The staining intensity was scored as 0 (negative), 1 (weak), 2 (medium), or 3 (strong). The extent of staining was scored as 0 (0%), 1 (1%-25%), 2 (26%-50%), 3 (51%-75%), or 4 (76%-100%), according to the percentages of positively stained areas in relation to the whole carcinoma area (or entire section for normal samples). The sum of the staining intensity and extent scores was used as the final staining scores (0-7) for fascin1. This scoring method is relatively simple and reproducible and gives highly concordant results between independent evaluators, as described in previous studies [23, 24] . For the purpose of statistical evaluation, tumors having a final staining score of ‡3 were considered to be positive. 
cell invasion assay
This assay was carried out as described before [26] . Briefly, warm serumfree media was added to the top chamber of the cell invasion chamber (Chemicon) to rehydrate the extracellular matrix layer for 2 h at room temperature. Tumor cells (1 · 10 5 cells) were added to the top chamber in serum-free media (300 ll). The bottom chamber was prepared with 10% FBS as a chemoattractant. After a 48-h incubation, noninvasive cells were removed with a cotton swab. The cells that had migrated through the membrane and adhered to the lower surface of the membrane were fixed with methanol and stained with hematoxylin. For quantification, the cells were counted under a microscope in five predetermined fields at ·200 magnification.
immunofluorescence Cells were cultured at low density on laminin-precoated coverslips and fixed with 4% paraformaldehyde for 20 min and treated with 0.25% Triton X-100 for 10 min. After blocking in 10% normal blocking serum at room temperature for 10 min, slides were incubated with fascin1 antibody (Chemicon) at 4°C overnight. After washing, cells were then coincubated with fluorescein isothiocyanate-conjugated anti-mouse secondary antibodies (Invitrogen) and Alexa Fluor 594 phalloidin (Invitrogen) for 30 min at room temperature, followed by staining with 4#,6-diamidino-2-phenylindole (Invitrogen).
statistical analysis
All statistical analyses were carried out using the SPSS statistical software package, version 10.0 (Abbott Laboratories, North Chicago, IL). The Mann-Whitney U test was used to analyze the relationship between fascin1 To investigate whether fascin1 abnormalities are linked to human NPC, we first analyzed fascin1 expression in 161 NPC tissues and 33 nasopharyngeal tissues. Fascin1 expression was observed in endothelial cells and lymphocytes mainly in the cytoplasm of the cells (Figure 1 ). Fascin1 was highly expressed in 95 (59.0%) of 161 NPC samples and 6 (18.2%) of 33 control samples. Fascin1 expression was significantly higher in NPC samples than that in control samples (Mann-Whitney U test; P < 0.001). In 4 of 33 nasopharyngeal epithelial tissues, fascin1 staining was highly positive in the basal layer and only slightly positive in the top layer ( Figure 1B ). In some NPC tissues, fascin1 was highly expressed in the invasive front of the tumors and slightly expressed in the tumor center area ( Figure 1D ). Consistent with the immunohistochemical results, fascin1 protein expression was low in the noncancerous normal epithelial specimens but was high in four NPC specimens and five NPC cell lines (Figure 2 ). Table 2 shows the association between fascin1 expression and the clinicopathological parameters. There was no significant correlation between fascin1 expression and age, gender, histological classification, T classification, distant metastasis, or tumor recurrence. However, fascin1 expression was significantly correlated with N classification (P < 0.001) and clinical stage (P < 0.001). Fascin1 expression was significantly higher in late-stage NPCs than in early-stage NPCs.
fascin1 expression is associated with N classification and clinical stage
inverse correlation between fascin1 overexpression and patients' survival
In the entire cohort, the OS rate for patients with high fascin1 expression was significantly lower than that for patients with low fascin1 expression (P < 0.001, log-rank test; Figure 3A ). The DFS rate for patients with high fascin1 expression was also significantly lower (P < 0.001, log-rank test; Figure 3B ). T classification, N classification, distant metastasis, and clinical stage were also significantly correlated with survival in KaplanMeier analysis and log-rank test (for T classification, P = 0.016; for N classification, P = 0.008; and for distant metastasis and clinical stage, P < 0.001). Univariate analysis showed that histological classification, T classification, N classification, clinical stage, distant metastasis, and fascin1 expression were statistically significant prognostic factors. Therefore, the multivariate model included histological classification, T classification, N classification, clinical stage, distant metastasis, and fascin1 expression. Multivariate analysis demonstrated that fascin1 expression was an independent prognostic factor ( Table 3) .
association between fascin1 expression and NPC cell invasiveness
The fact that fascin1 was significantly correlated with N classification prompted us to determine whether there was The values given in bold had statistically significant difference.
original article Annals of Oncology a relationship between fascin1 expression and NPC cell invasiveness. An RNA interference technique was used to knockdown endogenous fascin1 expression. After introduction of a fascin1 siRNA into 5-8F and CNE1 cells, fascin1 protein expression was substantially reduced (>70% inhibition) at 48 h after transfection ( Figure 4A) . A control siRNA (scrambled sequence) had no substantial effect on endogenous fascin1 expression. In the cell invasion assay, fascin1 knockdown cells exhibited significantly reduced invasiveness compared with cells transfected with the control siRNA (P < 0.01; Figure 4B ). Therefore, disruption of endogenous fascin1 expression resulted in suppression of cell invasiveness in NPC cells.
fascin1 knockdown reduces filopodia and lamellopodia in NPC cells
Immunofluorescence was used to examine the effects of fascin1 knockdown on cell filopodia and lamellopodia. In 5-8F and CNE1 cells seeded in laminin-precoated coverslips, fascin1 localized to the perinuclear cytoplasm and actin-rich membrane ruffles at the leading edge ( Figure 5 ). Phalloidin staining showed that filopodia and lamellopodia were observed at the leading edge in 5-8F and CNE1 cells ( Figure 5 ). However, in fascin1 knockdown cells, a significant decrease in the formation of filopodia and lamellopodia was observed ( Figure 5 ).
discussion
In this report, we have presented the first evidence demonstrating that an actin-bundling protein, fascin1, is overexpressed in NPC tissues compared with nasopharyngeal epithelial tissues. High expression level of fascin1 was significantly associated with tumor aggressiveness, including N classification and clinical stage, indicating that fascin1 may be correlated with tumor progression. Consistent with our findings, some studies have also reported that fascin1 is overexpressed in several epithelial carcinomas and associated with advanced tumor stage [22] . To date, the precise mechanism by which the up-regulation of fascin1 affects the process of carcinogenesis and tumor progression has not been clearly elucidated. Hashimoto et al. [22] indicated that transcriptional and/or post-transcriptional mechanisms are the more likely causes of fascin1 up-regulation compared with chromosomal aberrations. Vignjevic et al. [16] demonstrated that b-catenin/T cell factor signaling can transactivate the fascin1 promoter in human colorectal cancer cells. Dysregulation of the Wnt pathway is observed in NPC [27] and fascin1 up-regulation may contribute to Wnt pathway abnormality in NPC.
In this study, we have shown that fascin1 expression is closely associated with N classification, indicating that fascin1 plays a critical role in lymphatic metastasis. Moreover, in NPC, fascin1 was exclusively expressed in the invasive front of the cancerous tissue. In addition, the findings presented in this study demonstrate that disruption of endogenous fascin1 in NPC cell lines using siRNA technique greatly reduces cell invasive ability and decreases filopodial and lamellopodial formation, indicating that fascin1 plays a key role in NPC invasiveness. These results indicate that overexpression of fascin1 may contribute to the malignancy (invasion and metastasis) of NPC. Indeed, many reports have demonstrated a link between overexpression of fascin1 and increased cell motility and tumor invasiveness. In an in vitro study, overexpression of fascin1 in colonic adenocarcinoma cell lines increased the formation of dynamic cell protrusions, cell proliferation, and invasiveness [15] . On the other hand, suppression of fascin1 expression using siRNA resulted in fewer filopodia, altered pattern of cell protrusions, decreased Rac-dependent migration on laminin, and decreased turnover of focal adhesions [28] . Animal studies have shown a positive correlation between fascin1 expression and tumor invasiveness and metastases [16] .
Previous reports have also demonstrated that other biomarkers are independent prognostic indicators. Qian et al. [7] demonstrated in a study of 66 cases of NPC that high Met protein expression level correlates with poorer survival in latestage NPC and serves as an independent prognostic indicator, while Oudejans et al. [8] showed that the presence of many granzyme B-positive tumor-infiltrating lymphocytes (TILs) in a selected group of Indonesian NPC patients is a strong and stage-independent marker for a rapid fatal clinical outcome. It is reasonable to speculate that biomarkers influencing 
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angiogenesis, cell motility, immunity, and inflammation are all likely to contribute to the prognosis of NPC, and combination of different prognostic markers would be more accurate for the prognosis of NPC. Currently, the prognosis for patients with NPC mainly relies on clinical staging. However, NPC patients with the same clinical stage often present different clinical outcomes, indicating that the clinical stage is insufficient for precisely predicting the prognosis of NPC. In this study, we have shown a significant correlation between high fascin1 expression and shortened OS and DFS time in NPC patients. Multivariate analysis including T classification, N classification, distant metastasis, clinical stage, and fascin1 expression demonstrated that fascin1 expression was an independent prognostic factor, indicating that the prognostic significance of fascin1 is superior to that of clinical staging. Thus, fascin1 is a more valuable biomarker for NPC.
It seems surprising that the clinical stage had no independent prognostic value in a multivariate Cox regression model when fascin1 expression level was included but a significant correlation was found between the clinical stage and survival rate in a univariate analysis. This may be because no molecular criterion (e.g., VEGF or fascin1) is considered in clinical staging, or because biological markers may have more contributions to the prognosis than the clinical stage. In agreement with our finding, several reports also found that the clinical stage was not as significantly related to survival as other strong predictors were, such as a high percentage of granzyme B-positive TILs [8] and high expression of VEGF and survivin [29] . Consequently, in order to ensure the positive role of clinical stage in predicting prognosis, we think biological markers should be taken into consideration together with the clinical stage.
In summary, our results show that fascin1 is overexpressed in NPC tissues and that fascin1 expression is inversely correlated with survival and directly correlated with the malignant status of NPC. These results indicate that fascin1 expression status may be a useful clinical prognostic marker. Further studies are The values given in bold had statistically significant difference. NPC, nasopharyngeal carcinoma; HR, hazard ratio; CI, confidence interval. funding National Natural Science Foundation of China (30672312).
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